Development of a new therapy for allergic rhinitis using NKT cell-mediated immunity system
| Project/Area Number |
25861529
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Chiba University |
|---|
Principal Investigator |
YONEKURA Syuji 千葉大学, 医学部附属病院, 助教 (20400939)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | アレルギー性鼻炎 / 舌下免疫療法 / NKT細胞 / α-Galactosylceramide / Liposome / 新規治療 / liposome |
|---|
| Outline of Final Research Achievements |
The current study aimed to develop a new therapy for allergic rhinitis using NKT cell-mediated immunity system with enhanced therapeutic efficacy and a shortened duration of treatment without serious adverse events. TCRs of iNKT cells recognize monomorphic major histocompatibility complex (MHC) class I-like CD1d molecules on antigen-presenting cells (APCs), and glycolipid antigens such as α-galactosylceramide (α-GalCer) presented on CD1d preferentially activate iNKT Cells. In this study, we administered ovalbumin (OVA)- and α-GalCer-pulsed bone marrow-derived dendritic cells (BMDCs) into the oral submucosa of OVA-sensitized mice and examined the role of activated iNKT cells in an Allergi rhinitis mouse model. Administration of OVA/α-GalCer-pulsed BMDCs suppressed antigen-specific responses.
|
Report
(3 results)
Research Products
(5 results)
